Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 4.69 Billion | USD 20.00 Billion | 17.5% | 2023 |
FrequentlyAsked Questions
Antisense and RNA interference (RNAi) therapeutics are advanced molecular approaches used to target and modify gene expression for therapeutic purposes.
According to study, the Antisense and RNAi Therapeutics Market size was worth around USD 4.69 billion in 2023 and is predicted to grow to around USD 20.00 billion by 2032.
The CAGR value of Antisense and RNAi Therapeutics Market is expected to be around 17.5% during 2024-2032.
North America has been leading the Antisense and RNAi Therapeutics Market and is anticipated to continue on the dominant position in the years to come.
The Antisense and RNAi Therapeutics Market is led by players like Alnylam Pharmaceuticals, Isis Pharmaceuticals, Silence Therapeutics, Santaris, Antisense Therapeutics, and miRagen Therapeutics.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed